Current Rheumatology Reviews

Author(s): Abdel Gaffar A Mohammed*, Ayanda Gcelu, Farzana Moosajee, Stella Botha and Asgar Ali Kalla

DOI: 10.2174/1573397114666180406101850

DownloadDownload PDF Flyer Cite As
Immune Mediated Necrotizing Myopathy: Where do we Stand?

Page: [23 - 26] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Immune-mediated necrotizing myopathies (IMNMs) are a group of acquired autoimmune muscle disorders which are characterized by proximal muscle weakness, high levels of creatinine kinase, and myopathic findings on electromyogram (EMG). Muscle biopsy in IMNM differentiates it from the other subgroups of Idiopathic Inflammatory Myositis (IIM) by the presence of myofibre necrosis and prominent regeneration without substantial lymphocytic inflammatory infiltrates. Anti-signal recognition particle (SRP) and anti-3hydroxy-3 methylglutarylcoenzyme A reductase (HMGCR) autoantibodies were found in two-thirds of IMNM patients. In terms of treatment, IMNM is more resistant to conventional immunosuppressive treatment, therefore, other modalities of treatment such as Intravenous Immunoglobulin (IVIG) and rituximab are often required.

Keywords: Myopathy, anti-SRP, myositis, anti-HMGCR, IMNMs, EMG, IVIG.